In 2024, Darnytsia Produced Over 146 Million Packs of Medicines

In 2024, Darnytsia Pharmaceutical Company produced 146.5 million packs of medicines, which demonstrates the stability and high efficiency of the company in the conditions of a full-scale war.

The largest volume of tablets was produced - 93.7 million packs. Coated tablets accounted for 12 million packs, capsules - 4.8 million packs, and sachets - 0.9 million packs.

In 2024, Darnytsia also produced 14.9 million packs of ampoules, 6.4 million packs of drops and solutions and 8.1 million packs of infusions.

Sterile powders accounted for 1.8 million packs in the total production volume, and semi-solid dosage forms (creams, ointments, gels, pastes, suppositories) accounted for 3.9 million packs.

It should be reminded that Darnytsia has a wide range of effective medicines, focusing on the problems that are most relevant for Ukrainians. Today, these are cardiac and neurological diseases, as well as pain management issues.

The production facilities of the national pharmaceutical leader have been compliant with the requirements of Good Manufacturing Practice (GMP) since 2002. GMP certificates are constantly renewed by both national and European regulatory authorities. This is the evidence of high quality, efficacy and safety of Darnytsia’s medicines.

“In the context of a full-scale war, every year is a challenge. However, thanks to our highly skilled and engaged team, our investments in technology and innovation, we have maintained a stable production level to provide Ukrainians with high quality products. Darnytsia ensures the highest quality standards at every stage of production. Only in this way we can guarantee the efficacy, safety and reliability of our medicines, which is the basis of trust in them,” comments Liudmyla Denesiuk, Production Director at  Darnytsia Pharmaceutical Company.